AB0530 THE EFFECT OF MYCOPHENOLATE MOFETIL ON NON-RENAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS FROM 2014 TO 2018: OBSERVATION STUDY FROM KOREAN LUPUS NETWORK (KORNET) REGISTRY
Authors: Seong-Kyu Kim, Jung-Yoon Choe, Ui Hong Jung
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Mycophenolate mofetil (MMF) has been established to a potent therapeutic drug for regulate renal involvement in systemic lupus erythematosus (SLE). <h3>Objectives:</h3> The object of this study is to identify the effect of MMF on non-renal manifestations in SLE. <h3>Methods:</h3> The study population was total 439 SLE patients enrolled from Korean Lupus Network (KORNET) registry. The KORNET registry was followed up annually and completed from baseline survey to the 2<sup>nd</sup> visits from 2014 to 2018. In the subgroup analysis, the effect of MMF on clinical features was also evaluated in 110 patients with histologically confirmed lupus nephritis (LN). The changes of clinical features including mucocutaneous lesions, arthritis, serositis, neurologic disorder, and hematologic abnormalities were assessed between MMF and non-MMF groups during follow-up period. Statistical analysis was used by multiple comparison analysis, considering time, group, and interaction of follow-up time and treatment group. <h3>Results:</h3> There was significant difference of malar rash and renal disorder between MMF and non-MMF groups considering time and group in total SLE patients (p = 0.025 and p &lt; 0.001, respectively). In hematologic abnormalities, proportion of leukopenia was significantly different between two groups during follow-up periods (p<sub>time</sub> &lt; 0.001, p<sub>group</sub> &lt; 0.001, and p<sub>time &amp; group</sub> = 0.004). In 110 LN patients, there was not difference of non-renal clinical features between them. In contrast, proportion of leukopenia in patients with LN was significantly different between two groups during follow-up periods (p<sub>time</sub> &lt; 0.001, p<sub>group</sub> = 0.003, and p<sub>time &amp; group</sub> = 0.004). <h3>Conclusion:</h3> This study showed that MMF might be beneficial to treatment for hematologic abnormalities in SLE. <h3>References</h3> [1] Yahya F, Jasmin R, Ng CT, Cheah TE, Sockalingam S. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement. Int J Rheum Dis. 2013 Dec;16(6):724-30. [2] Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010 Jan;62(1):211-21. [3] Pisoni CN, Sanchez FJ, Karim Y, Cuadrado MJ, D'Cruz DP, Abbs IC, Khamasta MA, Hughes GR. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol. 2005 Jun;32(6):1047-52. [4] Moder KG, Amin S, Mazlumzadeh M, Crowson C, Ytterberg S. The effect of mycophenolate mofetil on patients with active non-renal SLE. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):932. <h3>Acknowledgement:</h3> none <h3>Disclosure of Interests:</h3> None declared